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Renal solitary extramedullary plasmacytomas belong to a group of plasma cell neoplasms, which
generally have been associated with renal cell carcinoma. We present a case report of a patient with
collision tumor histology of extramedullary plasmacytoma and clear cell renal cell carcinoma, the ﬁrst in
the known literature. Standard work-up for a plasma cell neoplasm was conducted and the mass was
resected. The patient remains disease-free at 28 months post-surgery. The report calls into question pre-
surgical renal mass biopsy protocol and suggests a relationship between renal cell carcinoma and plasma
cell neoplasms.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Renal solitary extramedullary plasmacytomas (SEPs) are rare
plasma cell neoplasms with only 25 cases reported in the litera-
ture.1 All prior cases have been primary or secondary SEPs with
uniform pathology. Here we discuss the evaluation, treatment and
28 month follow-up of a patient with a ﬁrst ever documented
collision tumor of extramedullary plasmacytoma and clear cell
renal cell carcinoma (RCC).
Case report
A 51-year-old obese (BMI ¼ 40) male initially presented to an
outside clinic for evaluation of intermittent gross hematuria.
Follow-up CT imaging (Fig. 1) revealed an 8 cm left renal mass,
Renal score R (3) þ E (2) þ N (3) þ A (p) þ L (3) ¼ 11p. Cytology in a
ﬁne needle biopsy was consistent with monoclonal plasma celloores UCSD Cancer Center,
Jolla, CA 93093-0987, USA.
st).
A 94305, USA.
Inc. This is an open access article uproliferation. Serum protein electrophoresis showed monoclonal
expansion of a small IgG. Further diagnostic PET/CT imaging was
negative for metastases.
The patient’s care was transferred to the UC San Diego oncologic
clinic for further evaluation. Initial work-up revealed a neck
acneiform rash, proteinuria, and elevated acute phase reactants.
Despite a normal CBC and negative PET/CT, a concern for mul-
tiple myeloma (MM) led to further investigations. A bone marrow
biopsy showed mild hypercellularity with a slightly increased
number of polyclonal plasma cells. Flow cytometry was negative
with 0.2% polyclonal plasma cells and a lack of abnormal or
increased immature cell populations. Cells had a 46 XY karyotype.
No evidence of monoclonal plasma cells was found. He subse-
quently underwent open left partial nephrectomy for presumed
extramedullary plasmacytoma and was discharged post-operative
day 6 without complication.
The resected mass (Fig. 2) had negative surgical margins with a
brown-yellow well-circumscribed lesion identiﬁed in the cortex.
Tumor dimensions were 8.0 x 7.2 x 6.5 cm. Tumor histology was
conducted with light microscopy and hemotoxylin and eosin (HE)
staining (Fig. 3A and B). The tumor pathology revealed a Fuhrman
grade 2 clear cell renal cell carcinoma, pT2aNxMs, with a distri-
bution of intermingled, nodular, and perivascular plasma cell pro-
liferation. The plasma cell nodules were found to be monoclonalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Contrast-enhanced computed tomography of the abdomen/pelvis at presentation. A) Axial view showing an 8 cm enhancing left mass. B) Coronal view indicating upper
pole location.
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histochemistry (IHC) and chromogenic in situ hybridization (CISH)
(Fig. 3C and D). However, single plasma cells scattered in other
areas were polyclonal. Epstein Barr Virus encoded RNA (EBER)
staining was negative.
At 28 month follow-up, the patient has no evidence of disease
and is without complication. Follow-up creatinine and GFR are
unchanged from baseline.Discussion
Here we report the ﬁrst known case of a collision tumor with
RCC clear cell and plasmacytoma. To our knowledge, this is the ﬁrst
reported ﬁnding of such pathology.
Limited data exist connecting RCC with plasmacytoma or MM.
However, a recent retrospective study following 57,190 patients
with primary RCC and 34,156 with primary MM found those with a
primary RCC have a higher risk of developing MM (incidence
ratio ¼ 1.51) and vice versa (incidence ratio ¼ 1.89).2 In our case
study, with a patient presenting with plasmacytoma and RCC, the
two neoplasms could have arisen by an initial lesion followed by the
development of the other, related tumor. Larger studies into
the duality between RCC and MM are needed to further elucidateFigure 2. Gross pathological ﬁndings post partial nephrectomy. A) View of intact mass. B)their true relationship. In the present literature, there are no com-
mon risk factors or mechanisms for RCC and plasmacytoma/MM.
Furthermore, the relationship of renal cell carcinoma and
extramedullary plasmacytoma in terms of origin and propagation is
still speculative. However, a potential mediator that could serve as a
common link is, IL-6. Acting as a pleiotrophic anti-apoptotic cyto-
kine, IL-6 has been implicated in a variety of tumors, including RCC
and MM, to play a signiﬁcant role in both RCC and plasmacytoma/
MM. Increased expression of IL-6 for both tumor types indicates a
source of potential further investigation for mechanisms of RCC and
plasma cell tumor development.3
According to AUA guidelines, in the setting of T1 renal masses,
needle biopsies are indicated to aid in patient counseling as well
as clinical decision making.4 However, given that our patient
presented with a clinical T2 mass, surgical treatment without
biopsy was potentially indicated. Additionally, even with ﬁne
needle aspiration (FNA) biopsy, the initial pathology was incor-
rect, which puts into question sole use of an FNA biopsy. The
improper FNA conducted by the outside clinic highlights an
example of how FNA biopsies of larger renal masses are not
indicated.
At 28 month follow-up, there has been no diagnosis of mul-
tiple myeloma. In a previous review of renal solitary extra-
medullary plasmacytomas, those treated by surgical resection hadMass dissected, showing areas of central necrosis and tumor incorporating cholesterol.
Figure 3. Microscopic examination for morphology, lambda chains, IHC and CISH, showing imbalance between kappa and lambda cell lineages (normally 3:2): A) H&E stain, 4. B)
H&E stain, 40; note clustered plasma cells amid renal clear cells. C) IHC Kappa stain, 10. D) IHC Lambda stain, 10.
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evaluation may be necessary to track the patient’s course for
future malignancy.
Conclusion
We present the ﬁrst case of a collision tumor consisting of SEP
intermingled within a clear cell RCC tumor, highlighting the need
for further study of RCC and plasma cell neoplasms. A needle biopsy
during initial work-up resulted in ambiguous results, calling into
question the validity of biopsies for large renal masses. Surgical
resection for renal SEP compares with equivalent survival rates for
radiation.
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